未来的新型药物：炎症性肠病中抗TNF药物之外的治疗方法
Novel agents in the future: Therapy beyond anti-TNF agents in inflammatory bowel disease.
作者信息
Peng Jiang Chen, Shen Jun, Ran Zhi Hua
机构信息
State Key Laboratory for Oncogenes and Related Genes, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Division of Gastroenterology and Hepatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Cancer Institute, Shanghai Institute of Digestive Disease, Shanghai Inflammatory Bowel Disease Research Center, Shanghai, China.
出版信息
J Dig Dis. 2014 Nov;15(11):585-90. doi: 10.1111/1751-2980.12193.
Anti-tumor necrosis factor (TNF)-α agents emerge as the hot spot in the last decade for treating patients with inflammatory bowel disease (IBD). The effect of anti-TNF-α agents is satisfactory; however, some patients fail to achieve clinical response. Fortunately, in recent years, great efforts have been made and multiple novel therapies have been developed in the treatment for IBD. In this article, we aim to introduce anti-TNF-α drugs as well as other novel treatments currently undergoing clinical trials for IBD.
抗肿瘤坏死因子（TNF）-α药物在过去十年中成为治疗炎症性肠病（IBD）患者的热点。抗TNF-α药物的疗效令人满意；然而，一些患者未能实现临床缓解。幸运的是，近年来，在IBD治疗方面已付出巨大努力并开发了多种新疗法。在本文中，我们旨在介绍抗TNF-α药物以及目前正在进行IBD临床试验的其他新疗法。
Zotero 插件